Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
http://finance.yahoo.com/news/bristol-myers-squibb-present-data-093900299.html
It is mostly talking about the E.U., but of course we have it here, or will anyways when it comes out.
What I want to know is why does it say GT 1, but yet it really only lists GT 1b specifically? I am a 1a, does that mean it won't work for me? I'm confused.
It is mostly talking about the E.U., but of course we have it here, or will anyways when it comes out.
What I want to know is why does it say GT 1, but yet it really only lists GT 1b specifically? I am a 1a, does that mean it won't work for me? I'm confused.
Conclusions
In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients. Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.
http://www.journal-of-hepatology.eu/article/S0168-8278(13)00744-7/abstract
However, I followed the Gilead Sovaldi/Ledipasvir trials closely - thousands of participants - and at least out of the people I knew - most were 1a's. One of them was 75 years old and on the verge of cirrhosis. So we KNOW that's gonna work for 1a's.
Now as for the insurance companies paying.....
We gotta put the pressure on for sure.
LOWER THE PRICE, Gilead.
Sovaldi/Ledipasvir is truly the big nuke. Hmmmm - I have to wonder if insurance companies are part of a plan to cull the sick and the elderly.